KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Clinical trial NCT06099821 · RECRUITING
Trial details
- NCT number
- NCT06099821
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-25
- Primary completion
- 2026-12-31
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.